Leonid Kagan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9030783/publications.pdf

Version: 2024-02-01

430874 434195 1,015 43 18 31 citations h-index g-index papers 43 43 43 1464 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prediction of Individual Analgesic Response to Intravenous Lidocaine in Painful Diabetic Peripheral Neuropathy. Clinical Journal of Pain, 2022, 38, 65-76.	1.9	4
2	A validated LC-MS/MS method for the quantitation of cefazolin in human adipose tissue: Application of EMR-Lipid sorbent as an efficient sample clean-up before mass spectrometric analyses. Journal of Pharmaceutical and Biomedical Analysis, 2022, 213, 114696.	2.8	3
3	Vitamin D Metabolism Gene Polymorphisms and Their Associated Disorders: A Literature Review. Current Drug Metabolism, 2022, 23, 630-651.	1.2	2
4	Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats. Pharmaceutical Research, 2022, 39, 1867-1880.	3.5	1
5	Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. British Journal of Clinical Pharmacology, 2021, 87, 516-526.	2.4	4
6	Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness. Antibiotics, 2021, 10, 739.	3.7	9
7	Administration in fed state but not controlled release in the colon increases oral bioavailability of DF030263, a promising drug candidate for chronic lymphocytic leukemia. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 106-112.	4.3	O
8	Evaluation and enhancement of standard equations for renal function estimation in individuals with components of metabolic disease. BMC Nephrology, 2021, 22, 389.	1.8	3
9	Intradermal and transdermal drug delivery using microneedles – Fabrication, performance evaluation and application to lymphatic delivery. Advanced Drug Delivery Reviews, 2020, 153, 195-215.	13.7	102
10	Is rat a good model for assessment of particulate-based taste-masked formulations?. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 146, 1-9.	4.3	5
11	Lymphatic Distribution of Etanercept Following Intravenous and Subcutaneous Delivery to Rats. Pharmaceutical Research, 2020, 37, 155.	3.5	5
12	Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study. Frontiers in Pharmacology, 2020, 11, 1103.	3.5	1
13	Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System. Pharmaceutical Research, 2020, 37, 205.	3.5	1
14	Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate. Applied Sciences (Switzerland), 2020, 10, 7283.	2.5	5
15	Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologicallyâ€based pharmacokinetic modeling. Biopharmaceutics and Drug Disposition, 2020, 41, 192-205.	1.9	9
16	Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients. Pharmaceutics, 2020, 12, 336.	4.5	0
17	Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatographyâ€ultraviolet method. Biomedical Chromatography, 2019, 33, e4653.	1.7	5
18	A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin. Scientific Reports, 2019, 9, 15760.	3.3	17

#	Article	IF	CITATIONS
19	Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient. Infection and Drug Resistance, 2019, Volume 12, 877-891.	2.7	6
20	Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. International Journal of Infectious Diseases, 2019, 84, 15-21.	3.3	7
21	Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition. Cancer Letters, 2019, 453, 57-73.	7.2	37
22	Prevention of paclitaxel-induced neuropathy by formulation approach. Journal of Controlled Release, 2019, 303, 109-116.	9.9	28
23	Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain, 2019, 160, 1835-1846.	4.2	30
24	Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 577-592.	1.8	12
25	Evaluation of the Effects of Animal Growth and Previous Exposure on the Pharmacokinetics of Rituximab in Rats. Journal of Pharmaceutical Sciences, 2018, 107, 1987-1994.	3.3	2
26	Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system. Journal of Controlled Release, 2018, 286, 10-19.	9.9	41
27	Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 38-42.	4.3	61
28	Harnessing the Action of Fibroblast Growth Factor21 as a Therapeutic Agent. Current Pharmacology Reports, 2017, 3, 26-35.	3.0	0
29	Cefoxitin Plasma and Subcutaneous Adipose Tissue Concentration in Patients Undergoing Sleeve Gastrectomy. Clinical Therapeutics, 2016, 38, 204-210.	2.5	7
30	Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thrombosis Journal, 2016, 14, 10.	2.1	11
31	Osteoarthritis disease progression model using six year followâ€up data from the osteoarthritis initiative. Journal of Clinical Pharmacology, 2015, 55, 269-278.	2.0	6
32	Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins. Drug Metabolism and Disposition, 2014, 42, 1890-1905.	3.3	67
33	Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. Pharmaceutical Research, 2014, 31, 35-45.	3.5	37
34	Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. Pharmaceutical Research, 2014, 31, 3265-3273.	3.5	24
35	Mechanisms of Subcutaneous Absorption of Rituximab in Rats. Drug Metabolism and Disposition, 2013, 41, 248-255.	3.3	41
36	Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics. Pharmaceutical Research, 2013, 30, 751-760.	3.5	29

#	Article	IF	CITATION
37	Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. Pharmaceutical Research, 2012, 29, 490-499.	3.5	82
38	Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data. AAPS Journal, 2011, 13, 255-64.	4.4	23
39	High-Dose Bupivacaine Remotely Loaded into Multivesicular Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma Concentrations After Subcutaneous Administration in Humans. Anesthesia and Analgesia, 2010, 110, 1018-1023.	2.2	68
40	Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. Pharmaceutical Research, 2010, 27, 920-932.	3.5	42
41	Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulmonary Pharmacology and Therapeutics, 2009, 22, 260-265.	2.6	20
42	The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 759-765.	4.3	89
43	Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans. Journal of Controlled Release, 2006, 113, 208-215.	9.9	69